Sensei Biotherapeutics, Inc. (SNSE), a clinical-stage biotechnology company, on Wednesday provided an update on its lead program, solnerstotug or SNS-101, an innovative antibody targeting the VISTA immune checkpoint in cancer immunotherapy.
Key updates include:
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com